Marta E Polak

Summary

Publications

  1. ncbi Melanoma vaccines: The problems of local immunosuppression
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, United Kingdom
    Hum Immunol 70:331-9. 2009
  2. ncbi Isolation of inflammatory cells from human tumours
    Marta E Polak
    Division of Infection, Inflammation and Immunity, University of Southampton School of Medicine, Southampton, UK
    Methods Mol Biol 731:201-8. 2011
  3. ncbi Activation of tonsil dendritic cells with immuno-adjuvants
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
    BMC Immunol 9:10. 2008
  4. ncbi Presence and phenotype of dendritic cells in uveal melanoma
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Southwick Hill, Portsmouth PO6 3LY, UK
    Br J Ophthalmol 91:971-6. 2007
  5. ncbi Presence and maturity of dendritic cells in melanoma lymph node metastases
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
    J Pathol 207:83-90. 2005
  6. ncbi Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
    Sharon Glaysher
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK
    BMC Cancer 9:300. 2009

Detail Information

Publications6

  1. ncbi Melanoma vaccines: The problems of local immunosuppression
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, United Kingdom
    Hum Immunol 70:331-9. 2009
    ..Nevertheless, if these problems can be overcome, it seems likely that the efficacy of melanoma vaccines could be greatly enhanced...
  2. ncbi Isolation of inflammatory cells from human tumours
    Marta E Polak
    Division of Infection, Inflammation and Immunity, University of Southampton School of Medicine, Southampton, UK
    Methods Mol Biol 731:201-8. 2011
    ..We recommend density centrifugation for initial enrichment, followed by specific magnetic bead negative or positive panning with leukocyte and tumour cell selective antibodies...
  3. ncbi Activation of tonsil dendritic cells with immuno-adjuvants
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
    BMC Immunol 9:10. 2008
    ..In humans, although much is known about the responses of monocyte derived DC, relatively little is known about effect of immuno-stimulatory adjuvants on DC found in tonsil...
  4. ncbi Presence and phenotype of dendritic cells in uveal melanoma
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Southwick Hill, Portsmouth PO6 3LY, UK
    Br J Ophthalmol 91:971-6. 2007
    ..Previous studies on cutaneous melanoma have shown the presence of tolerogenic dendritic cells (DCs), which could play an important role in the progression of the tumour...
  5. ncbi Presence and maturity of dendritic cells in melanoma lymph node metastases
    Marta E Polak
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
    J Pathol 207:83-90. 2005
    ..Immature DCs, characterized by phenotypic and morphological features, are therefore present within the tumour deposits in lymph nodes infiltrated by melanoma and may specifically modulate the anti-melanoma immune response...
  6. ncbi Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
    Sharon Glaysher
    Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK
    BMC Cancer 9:300. 2009
    ..This study has tested the hypothesis that the molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors...